和譽招股中,一手入場費約25171元
和譽開曼 (02256) 今日(9月30日)起至10月6日招股。專注於小分子腫瘤療法的內地臨牀階段生物製藥公司和譽開曼計劃發行1.4億股,一成於香港作公開發售,集資最多17.5億元,招股價介乎12.16元至12.46元,一手2000股,每手入場費25171.12元。和譽開曼預期於10月13日掛牌。
和譽開曼爲一家臨牀階段的生物製藥公司,致力於發現及開發創新且差異化的小分子腫瘤療法。自2016年成立以來,已戰略性地設計及開發由14個專注於腫瘤學的候選藥物組成的管線,包括五種處於臨牀階段的候選藥物。
截至2020年12月31日止,和譽開曼未有主營業務收入,稅前虧損7.1億元人民幣,絕大部分虧損來自研發開支及行政開支。
和譽開曼指,所得款項淨額19.7%將用於進行中的及未來的研發;32.6%用於核心候選產品ABSK091的未來持續研發活動;28%用於未來持續研發活動;8.4%用於臨牀前研究;6.3%用於建造製造設施及租用新的研發設施;5%用作營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.